Treatment of lupus: Impact on quality of life

Current Rheumatology Reports

Volumn 13, Issue 4, 2011, Pages 324-337

  Toloza, Sergio M A ^b   Sequeira, Winston ^a   Jolly, Meenakshi ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Hospital Interzonal de Agudos San Juan Bautista   (Argentina)

Author keywords

Health related quality of life; Lupus; Nonpharmacologic studies; Pharmacologic studies; Quality of life; Systemic lupus erythematosus; Treatment; Treatment impact

Indexed keywords

ABETIMUS; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FOLIC ACID; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PLACEBO; PRASTERONE; PREDNISOLONE; RITUXIMAB; TESTOSTERONE;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANDROGEN DEFICIENCY; ATTITUDE TO ILLNESS; CLINICAL FEATURE; COGNITIVE THERAPY; DOCTOR PATIENT RELATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; HUMAN; INTERVENTION STUDY; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; PATIENT CARE; PHYSICAL ACTIVITY; QUALITY OF LIFE; REVIEW; SHORT FORM 36; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADAPTATION, PSYCHOLOGICAL; COMPLEMENTARY THERAPIES; FEMALE; HEALTH STATUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 79960573426     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0189-3     Document Type: Review

References (32)

1. M Jolly 2005 How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 32 1706 8 16142864 (Pubitemid 41324807)
2. V Strand D Gladman D Isenberg, et al. 2000 Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology Lupus 9 322 7 10878722 10.1191/096120300678828424 1:STN:280:DC%2BD3czosVemtw%3D%3D (Pubitemid 30389032)
3. JN Siegel 1999 Development of an FDA guidance document for clinical trials in SLE Lupus 8 581 5 10568893 10.1191/096120399680411425 1:STN:280:DC%2BD3c%2FjvVaiug%3D%3D (Pubitemid 29520522)
4. J Thumboo V Strand 2007 Health-related quality of life in patients with systemic lupus erythematosus: an update Ann Acad Med Singapore 36 115 22 17364078 (Pubitemid 46640263)
5. SM Toloza M Jolly GS Alarcón 2010 Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: cross-cultural issues Curr Rheumatol Rep 12 4 237 49 20461481 10.1007/s11926-010-0110-5 This is a review of the literature on HRQoL studies in SLE showing that most studies pertaining to HRQoL are from developed Western societies. The majority have been conducted in women using the SF-36, a generic HRQoL instrument that has been shown not to be sensitive to change in lupus. Also, existent lupus-specific HRQoL measures have not yet been used in SLE clinical trials
6. D Isenberg C Gordon J Merrill, et al. 2008 New therapies in systemic lupus erythematosus-trials, troubles and tribulations ⋯ working towards a solution Lupus 17 967 70 18852218 10.1177/0961203308095139 1:STN:280: DC%2BD1cnlslKiuw%3D%3D
7. DJ Wallace 2009 New therapies in systemic lupus erythematosus-trials, troubles and tribulations-working towards a solution: part 2-the politically incorrect versión Lupus 18 101 3 19151109 10.1177/0961203308100843 1:STN:280:DC%2BD1M%2FotFSksQ%3D%3D This is an excellent editorial explaining why lupus trials studying useful therapeutic agents have failed in the past 10 years. It also provides additional suggestions based on the author's extensive SLE experience to ensure the success of a new therapeutic agent
8. S de Achaval ME Suarez-Almazor 2010 Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus Int J Clin Rheumtol 5 313 26 20676388 10.2217/ijr.10.15
9. GS Alarcón G McGwin Jr K Brooks, et al. 2002 Systemic lupus erythematosus in three ethnic groups. XI. Sources of discrepancy in perception of disease activity: a comparison of physician and patient visual analog scale scores Arthritis Rheum 47 408 13 12209488 10.1002/art.10512 (Pubitemid 34856130)
10. M Jolly TO Utset 2004 Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? Lupus 13 924 6 15645747 10.1191/0961203304lu2034oa 1:STN:280:DC%2BD2M%2FhvFCrsA%3D%3D (Pubitemid 39664951)
11. N Navarrete-Navarrete M Peralta-Ramírez J Sabio, et al. 2010 Quality-of-life predictor factors in patients with SLE and their modification after cognitive behavioural therapy Lupus 19 1632 9 20841339 10.1177/0961203310378413 1:STN:280:DC%2BC3cbpvVahsQ%3D%3D This study stresses the importance of factors such as stress and anxiety in assessing HRQoL and how they can be modified by a cognitive-behavioral therapy program irrespective of disease activity
12. Bennett JK, Fuertes JN, Keitel M, Phillips R. The role of patient attachment and working alliance on patient adherence, satisfaction, and health-related quality of life in lupus treatment. Patient Educ Couns. 2010 Sep 22 (Epub ahead of print)
13. • Harrison M, Dale N, Haque S, et al. Improving health-related quality of life in patients with systemic lupus erythematosus (SLE): the role of disease control, steroid reduction and smoking cessation. Presented at the LXXIV American College Annual Scientific Meeting, Atlanta, USA; November 7-11, 2010. This was a study showing that mean SF-6D scores did not change over a 5-year follow-up period; however, there are groups of patients who experience clinically important improvement or deterioration in HRQoL within this population. Gains in HRQoL may be obtained with better disease control, by reducing or stopping steroid therapy, and through smoking cessation.
14. Abrahão M, Montenegro-Rodrigues R, Marangoni R, et al. Impact of physical activity program in systemic lupus erythematosus. Presented at the LXXIII American College Annual Scientific Meeting, Philadelphia, USA; October 17-21, 2010
15. C Boström B Dupré P Tengvar, et al. 2008 Aerobic capacity correlates to self-assessed physical function but not to overall disease activity or organ damage in women with systemic lupus erythematosus with low-to-moderate disease activity and organ damage Lupus 17 2 100 4 18250132 10.1177/0961203307085670 (Pubitemid 351346443)
16. •• Strand V, Levy RA, Cervera R, et al. Belimumab, a BLyS-specific inhibitor, improved fatigue and SF-36 physical and mental component summary scores in patients with SLE: BLISS-76 and -52 Studies. Presented at the LXXIV American College Annual Scientific Meeting, Atlanta, USA; November 7-11, 2010. This article detailed phase 3, multicenter, randomized, double-blind, placebo-controlled studies among patients with seropositive SLE receiving belimumab treatment who had improvement in SF-36 PCS and MCS scores at week 52, as well as improvement in fatigue as early as week 8.
17. A Hartkamp R Geenen G Godaert, et al. 2010 Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescient systemic lupus erythematosus: a randomised controlled trial Ann Rheum Dis 69 1144 7 19854713 10.1136/ard.2009.117036 1:STN:280:DC%2BC3czls1ygsA%3D%3D This was a double-blind, randomized, placebo-controlled study of 60 female inactive SLE patients receiving 200 mg oral DHEA or placebo that showed an absence of therapeutic effect on fatigue and well-being in clinically quiescent disease
18. B Griffiths P Emery V Ryan, et al. 2010 The BILAG multi-centre open randomized controlled trial comparing cyclosporin vs. azathioprine in patients with severe SLE Rheumatology 49 723 32 20081225 10.1093/rheumatology/kep396 1:CAS:528:DC%2BC3cXjslegtLo%3D This was a clinical trial conducted to determine whether low-dose cyclosporin was a more effective corticosteroid-sparing agent than azathioprine in SLE patients. The study showed that both drugs were effective as corticosteroid-sparing agents; however, clinical and laboratory monitoring will be more stringent with cyclosporin. No significant differences were detected for change in quality of life
19. JT Merrill CM Neuwelt DJ Wallace, et al. 2010 Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Arthritis Rheum 62 222 33 20039413 10.1002/art.27233 1:CAS:528:DC%2BC3cXhtFGnurfP The EXPLORER trial tested the efficacy and safety of rituximab compared with placebo in patients with moderately to severely active extrarenal SLE. It showed no differences between placebo and rituximab in the primary and secondary end points, including quality of life
20. SS Uppal SJ Hayat R Raghupathy 2009 Efficacy and safety of infliximab in active SLE: a pilot study Lupus 18 690 7 19502264 10.1177/0961203309102557 1:CAS:528:DC%2BD1MXptVOjtb4%3D
21. P Fortin M Abrahamowicz D Ferland, et al. 2008 Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial Arthritis Rheum 59 1796 804 19035431 10.1002/art.24068 1:CAS:528:DC%2BD1MXnsV2rtg%3D%3D
22. KB Dussán L Magder RA Brodsky, et al. 2008 High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures Lupus 17 1079 85 19029275 10.1177/0961203308093828
23. MM Medeiros AP Menezes VA Silveira, et al. 2008 Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy Eur J Intern Med 19 122 8 18249308 10.1016/j.ejim.2007.06.012 1:CAS:528:DC%2BD1cXhtlyms74%3D
24. MH Cardiel JA Tumlin RA Furie, et al. 2008 Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial Arthritis Rheum 58 2470 80 18668592 10.1002/art.23673 1:CAS:528:DC%2BD1cXhtVCjtbfF
25. GS Alarcón G McGwin AM Bertoli 2007 Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) Ann Rheum Dis 66 1168 72 17389655 10.1136/ard.2006.068676 (Pubitemid 47309732)
26. M Jolly D Sandler W Sequeira, et al. 2009 Hydroxy-Chloroquine use and disease specific health related quality of life in systemic lupus erythematosus Arthritis Rheum 60S 10 S108 The beneficial effects of hydroxychloroquine in preventing major lupus flares, retarding damage accrual, and improving patient survival are well-known; however, no demonstrable effect on either the LupusQoL-US or the LupusPRO for hydroxychloroquine could be demonstrated in this study
27. MA Petri PJ Mease JT Merrill, et al. 2004 Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus Arthritis Rheum 50 2858 68 15452837 10.1002/art.20427 1:CAS:528: DC%2BD2cXoslGgsLo%3D (Pubitemid 39209523)
28. C Gordon DJ Wallace S Shinada, et al. 2008 Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus Rheumatology 47 334 8 18238794 10.1093/rheumatology/kem342 1:CAS:528: DC%2BD1cXitlKkurs%3D (Pubitemid 351267202)
29. AD Moore MA Petri S Manzi, et al. 2000 The use of alternative therapies in patients with systemic lupus erythematosus. Trination Study Group Arthritis Rheum 43 1410 8 10857802 10.1002/1529-0131(200006)43:6<1410::AID-ANR27>3. 0.CO;2-U 1:STN:280:DC%2BD3czhtl2ntw%3D%3D (Pubitemid 30416329)
30. J Alvarez-Nemegyei A Bautista-Botello J Dávila-Velázquez 2009 Association of complementary or alternative medicine use with quality of life, functional status or cumulated damage in chronic rheumatic diseases Clin Rheumatol 28 547 51 19139949 10.1007/s10067-008-1082-y
31. CT Chou 2010 Alternative therapies: what role do they have in the management of lupus? Lupus 19 1425 9 20947552 10.1177/0961203310379872
32. C Greco A Kao K Maksimowicz-McKinnon, et al. 2008 Acupuncture for systemic lupus erythematosus: a pilot RCT feasibility and safety study Lupus 17 1108 16 19029279 10.1177/0961203308093921 1:STN:280:DC%2BD1cjmtFGgsQ%3D%3D